Literature DB >> 27569207

Bronchial Artery Angiogenesis Drives Lung Tumor Growth.

Lindsey Eldridge1, Aigul Moldobaeva1, Qiong Zhong1, John Jenkins1, Michael Snyder1, Robert H Brown1, Wayne Mitzner1, Elizabeth M Wagner2.   

Abstract

Angiogenesis is vital for tumor growth but in well-vascularized organs such as the lung its importance is unclear. This situation is complicated by the fact that the lung has two separate circulations, the pulmonary and the systemic bronchial circulation. There are few relevant animal models of non-small cell lung cancer, which can be used to study the lung's complex circulations, and mice, lacking a systemic bronchial circulation cannot be used. We report here a novel orthotopic model of non-small cell lung cancer in rats, where we have studied the separate contributions of each of the two circulations for lung tumor growth. Results show that bronchial artery perfusion, quantified by fluorescent microspheres (206% increase in large tumors) or high-resolution computed tomography scans (276% increase in large tumors), parallels the growth in tumor volume, whereas pulmonary artery perfusion remained unchanged. Ablation of the bronchial artery after the initiation of tumor growth resulted in a decrease in tumor volume over a subsequent course of 4 weeks. These results demonstrate that although the existing pulmonary circulation can supply the metabolic needs for tumor initiation, further growth of the tumor requires angiogenesis from the highly proliferative bronchial circulation. This model may be useful to investigate new therapeutic approaches that target specifically the bronchial circulation. Cancer Res; 76(20); 5962-9. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2016        PMID: 27569207      PMCID: PMC5065771          DOI: 10.1158/0008-5472.CAN-16-1131

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  34 in total

Review 1.  Tumor angiogenesis: therapeutic implications.

Authors:  J Folkman
Journal:  N Engl J Med       Date:  1971-11-18       Impact factor: 91.245

2.  Bronchial artery infusion therapy for lung cancer.

Authors:  T Neyazaki; M Ikeda; Y Seki; N Egawa; C Suzuki
Journal:  Cancer       Date:  1969-11       Impact factor: 6.860

3.  Whole-tumor perfusion CT in patients with advanced lung adenocarcinoma treated with conventional and antiangiogenetic chemotherapy: initial experience.

Authors:  Francesco Fraioli; Michele Anzidei; Fulvio Zaccagna; Maria Luisa Mennini; Goffredo Serra; Bruno Gori; Flavia Longo; Carlo Catalano; Roberto Passariello
Journal:  Radiology       Date:  2011-02-25       Impact factor: 11.105

4.  Analysis of tumor vessel supply in Lewis lung carcinoma in mice by fluorescent microsphere distribution and imaging with micro- and flat-panel computed tomography.

Authors:  Rajkumar Savai; Joachim C Wolf; Susanne Greschus; Bastian G Eul; Ralph T Schermuly; Jörg Hänze; Robert Voswinckel; Alexander C Langheinrich; Friedrich Grimminger; Horst Traupe; Werner Seeger; Frank Rose
Journal:  Am J Pathol       Date:  2005-10       Impact factor: 4.307

5.  Treatment of lung cancer using clinically relevant oral doses of the cyclooxygenase-2 inhibitor rofecoxib: potential value as adjuvant therapy after surgery.

Authors:  Tomoyuki Tanaka; Peter A Delong; Kunjlata Amin; Adam Henry; Robert Kruklitis; Veena Kapoor; Larry R Kaiser; Steven M Albelda
Journal:  Ann Surg       Date:  2005-01       Impact factor: 12.969

6.  miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma.

Authors:  Andrea L Kasinski; Frank J Slack
Journal:  Cancer Res       Date:  2012-09-10       Impact factor: 12.701

7.  MIP-2 causes differential activation of RhoA in mouse aortic versus pulmonary artery endothelial cells.

Authors:  Aigul Moldobaeva; Amy Baek; Elizabeth M Wagner
Journal:  Microvasc Res       Date:  2007-07-06       Impact factor: 3.514

Review 8.  Review of the current targeted therapies for non-small-cell lung cancer.

Authors:  Kim-Son H Nguyen; Joel W Neal; Heather Wakelee
Journal:  World J Clin Oncol       Date:  2014-10-10

9.  Suppression of lung cancer tumor growth in a nude mouse model by the Ras inhibitor salirasib (farnesylthiosalicylic acid).

Authors:  Adi Zundelevich; Galit Elad-Sfadia; Ronit Haklai; Yoel Kloog
Journal:  Mol Cancer Ther       Date:  2007-05-31       Impact factor: 6.261

10.  Anti-angiogenic efficacy of 5'-triphosphate siRNA combining VEGF silencing and RIG-I activation in NSCLCs.

Authors:  Dongmei Yuan; Mao Xia; Gang Meng; Chun Xu; Yong Song; Jiwu Wei
Journal:  Oncotarget       Date:  2015-10-06
View more
  12 in total

1.  Pre-treatment serum bicarbonate predicts for primary tumor control after stereotactic body radiation therapy in patients with localized non-small cell lung cancer.

Authors:  Nikhil Sebastian; Trudy Wu; Erin Driscoll; Henning Willers; Suzanne Kelly; Hima Bindu Musunuru; Xiaokui Mo; Yubo Tan; Jose Bazan; Karl Haglund; Meng Xu-Welliver; Andrew M Baschnagel; Andrew Ju; Florence Keane; Terence M Williams
Journal:  Radiother Oncol       Date:  2019-06-05       Impact factor: 6.280

2.  Bronchial Artery Chemoembolization With Radiopaque Doxorubicin Eluding Beads in Patients With Malignant Hemoptysis from Metastatic Lung Cancer.

Authors:  Nariman Nezami; Christos Georgiades; Kelvin K Hong; Ji Buethe
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

3.  Establishment of a large animal model for research on transbronchial arterial intervention for lung cancer.

Authors:  Zhichao Sun; Xiao An; Hongchao Liu; Weihua Dong; Xiangsheng Xiao
Journal:  Diagn Interv Radiol       Date:  2021-07       Impact factor: 2.630

4.  Angiogenesis Inhibitors for the Treatment of Ovarian Cancer: An Updated Systematic Review and Meta-analysis of Randomized Controlled Trials.

Authors:  Haihong Wang; Tie Xu; Lifen Zheng; Guiling Li
Journal:  Int J Gynecol Cancer       Date:  2018-06       Impact factor: 3.437

Review 5.  The roles of tumor-derived exosomes in non-small cell lung cancer and their clinical implications.

Authors:  Hongmei Zheng; Yuting Zhan; Sile Liu; Junmi Lu; Jiadi Luo; Juan Feng; Songqing Fan
Journal:  J Exp Clin Cancer Res       Date:  2018-09-14

6.  Time Difference of Arrival on Contrast-Enhanced Ultrasound in Distinguishing Benign Inflammation From Malignant Peripheral Pulmonary Lesions.

Authors:  Min Tang; Qianrong Xie; Jiasi Wang; Xiaoyu Zhai; Hong Lin; Xiaoxue Zheng; Guoli Wei; Yan Tang; Fanwei Zeng; Yanpeng Chu; Jianqiong Song; Jianqiang Cai; Fanxin Zeng
Journal:  Front Oncol       Date:  2020-11-12       Impact factor: 6.244

Review 7.  Progress on pivotal role and application of exosome in lung cancer carcinogenesis, diagnosis, therapy and prognosis.

Authors:  Ming-Yue Li; Li-Zhong Liu; Ming Dong
Journal:  Mol Cancer       Date:  2021-01-27       Impact factor: 27.401

8.  Perfusion Patterns of Peripheral Pulmonary Lesions in COVID-19 Patients Using Contrast-Enhanced Ultrasound (CEUS): A Case Series.

Authors:  Ehsan Safai Zadeh; Björn Beutel; Christoph Frank Dietrich; Corinna Ulrike Keber; Katharina Paulina Huber; Christian Görg; Corinna Trenker
Journal:  J Ultrasound Med       Date:  2021-01-18       Impact factor: 2.754

9.  In vivo targeting of lentiviral vectors pseudotyped with the Tupaia paramyxovirus H glycoprotein bearing a cell-specific ligand.

Authors:  Takele Argaw; Michael P Marino; Andrew Timmons; Lindsey Eldridge; Kazuyo Takeda; Pingjuan Li; Anna Kwilas; Wu Ou; Jakob Reiser
Journal:  Mol Ther Methods Clin Dev       Date:  2021-04-24       Impact factor: 6.698

10.  CT Perfusion in Patients with Lung Cancer: Squamous Cell Carcinoma and Adenocarcinoma Show a Different Blood Flow.

Authors:  Alessandro Bevilacqua; Giampaolo Gavelli; Serena Baiocco; Domenico Barone
Journal:  Biomed Res Int       Date:  2018-09-03       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.